Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Germany
Poland
Portugal
The Netherlands
Drug_FXSPreMut
Preclinical approaches towards therapeutic intervention for fragile X premutation carriers

Project Coordinator

Erasmus University Medical Center
Rotterdam
The Netherlands

Partners

Oliver Stork Otto-von-Guericke-Universität Magdeburg Magdeburg, Germany
Nicolas Charlet-Berguerand Department of Translational Medicine IGBMC Illkrich, France
Cecile Martinat INSERM, I-STEM, UEVE UMR 861, AFM Genopole Campus 1 Evry, France
Krzysztof Sobczak Adam Mickiewicz University Poznan, Poland
Alfonso Nuno TechnoPhage, S.A Lisbon, Portugal

The Fragile X gene (FMR1) is polymorphic for the number of CGG trinucleotide repeats in the 5’-untranslated region. Repeat sizes in the general population range between 5-55 CGG repeats. In Fragile X syndrome repeat expansions exceed 200, silencing expression of FMR1, resulting in intellectual disability. Carriers of the Fragile X premutation have between 55-200 repeats in the FMR1 gene and are at risk for developing Fragile X-associated tremor/ataxia syndrome (FXTAS). FXTAS is a late onset neurodegenerative disorder causing tremor, ataxia, brain pathology, cognitive loss, dementia and early death in some individuals. The proposed pathological mechanism is a toxic RNA gain-of-function model in which mRNAs containing expanded CGG repeats accumulate in neuronal nuclear aggregates. These RNA aggregates sequester specific RNA-binding proteins, thus impairing their normal cellular functions and ultimately resulting in neuronal death. Currently, no treatment exists for FXTAS. As the potential molecular target is well defined (i.e. the mutant FMR1 mRNA), FXTAS is highly amenable to the development of gene targeting therapy. Therefore, the primary objective of this proposal is to establish critical developmental periods when disease might be halted or reversed and to identify pharmacological and molecular compounds to alleviate expanded CGG-induced toxicity. Collectively, the partners of this multidisciplinary consortium have excellent in vivo and in vitro models of FXTAS, valuable resources and state-of-the-art and emerging technologies available.

E-Rare 2012 - Created by Toussaint Biger